First Study in Humans With GSK206136

A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK206136 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin-1 Receptor Occupancy

This is the first study in humans with GSK206136 to evaluate what effects: good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body (pharmacokinetics). Also the study aims to investigate the penetration of the drug in the human brain by using PET (Positron Emission Tomography) imaging technology

Inclusion Criteria:

• Healthy males aged 18-45 years, limited to 25-40 years of age for PET section

Exclusion Criteria:

• The subject has a positive: drug/alcohol, Hepatitis, HIV screen..
• The subject has a history of psychiatric illness suicidal attempts or behaviour.
• Abuse of alcohol.
• Clinically significant laboratory, ECG abnormality;
• The subject has recently received an investigational.
• Use of prescription or non-prescription drugs,
• History or presence of allergy to the study drug or drugs of this class,
• Donation of more than 500 mL blood within the 90 days before dosing.
• An unwillingness of male subjects to comply with contraceptive requirements
• Average daily caffeine intake exceeding Protocol requirements.